CSIMarket
 
Becton Dickinson And Company  (BDX)
Other Ticker:  
 
 

Becton Dickinson's Customers Performance

BDX

 
BDX's Source of Revenues In the Q1, Becton Dickinson And Company's corporate clients experienced a reduction by -3.69 % in their costs of revenue, compared to a year ago, sequentially costs of revenue were trimmed by -39.41 %. During the corresponding time, Becton Dickinson And Company recorded revenue increase by 4.65 % year on year, sequentially revenue grew by 7.2 %. While revenue at the Becton Dickinson And Company's corporate clients recorded rose by 3.89 % year on year, sequentially revenue fell by -25.79 %.

List of BDX Customers




Customers of Becton Dickinson And Company saw their costs of revenue decrease by -3.69 % in Q1 compare to a year ago, sequentially costs of revenue were trimmed by -39.41 %, for the same period Becton Dickinson And Company recorded revenue increase by 4.65 % year on year, sequentially revenue grew by 7.2 %.

List of BDX Customers



   
Customers Net Income fell in Q1 by Customers Net margin fell to %
-10.8 % 4.44 %
Customers Net Income fell in Q1 by -10.8 %


Customers Net margin fell to 4.44 % 4.44 %



Becton Dickinson's Customers, Q1 2024 Revenue Growth By Industry
Customers in Agricultural Production Industry      78.11 %
Customers in Biotechnology & Pharmaceuticals Industry      21.98 %
Customers in Healthcare Facilities Industry      6.9 %
Customers in Major Pharmaceutical Preparations Industry      0.7 %
Customers in Medical Laboratories Industry -9.27 %   
Customers in IT Infrastructure Industry      13.3 %
Customers in Pharmacy Services & Retail Drugstore Industry      3.7 %
Customers in Grocery Stores Industry  
     
• Customers Valuation • Customers Mgmt. Effect.


Becton Dickinson's Comment on Sales, Marketing and Customers



BD’s products are marketed in the United States and internationally through independent distribution channels and directly to end-users by BD and independent sales representatives. Order backlog is not material to BD’s business inasmuch as orders for BD products generally are received and filled on a current basis, except for items temporarily out of stock. BD’s worldwide sales are not generally seasonal, with the exception of certain medical devices in the BD Medical segment, and respiratory and flu diagnostic products in the BD Diagnostics segment, which relate to seasonal diseases such as influenza.

Most of our customers and healthcare providers typically rely on third-party payers, including government programs and private health insurance plans, to reimburse some or all of the cost of the procedures, products and services they provide. Our devices are subject to worldwide regulations regarding reimbursement developed by government agencies, including the Centers for Medicare and Medicaid Services (CMS) in the United States; the National Health Service in the United Kingdom; the Joint Federal Committee in Germany; the Commission d’Evaluation des Produits et prestations in France; the Ministry for Health, Labor and Welfare in Japan; the Ministry of Health and the National Development and Reform Commission in China; among many others. In addition, our devices are also subject to reimbursement policies issued by private insurance companies and managed care organizations. The manner and level of reimbursement in any given case may depend on the site of care, the procedure(s) performed, the final patient diagnosis, the device(s) and/or drug(s) utilized, the available budget, or a combination of these factors, and coverage and payment levels are determined at each payer’s discretion. The coverage policies and reimbursement levels of these third-party payers may impact the decisions of healthcare providers and facilities regarding which medical products they purchase and the prices they are willing to pay for those products. Thus, changes in reimbursement levels or methods may either positively or negatively impact sales of BD products.

While BD is actively engaged in promoting the value propositions of its products for payer, provider, and patient stakeholders, and it employs various efforts and resources to positively impact coverage, coding and payment processes in this regard, it has no direct control over payer decision-making with respect to coverage and payment levels for BD products. Many third-party payers are seeking to control the growth of healthcare expenditures and have developed specific payment and delivery mechanisms to support these cost control efforts. These mechanisms include payment reductions, pay for performance measures, quality-based performance payments, restrictive coverage policies, bidding and tender mechanics, studies to compare the effectiveness of therapies and use of technology assessments. These changes have created an increased emphasis on the delivery of more cost-effective and quality-driven healthcare. As government programs, including CMS and many other national healthcare programs, seek to expand healthcare coverage for their citizens, they have at the same time sought to control costs by limiting the amount of reimbursement they will pay for particular procedures, products or services.

As BD’s product offerings are diverse across many healthcare settings, they are affected to varying degrees by the many payment systems. Therefore, individual countries, product lines or product classes may be impacted by changes to these systems. Notably the Patient Protection and Affordable Care Act (“PPACA”) provides for numerous, substantive changes to U.S. healthcare payment systems. The law focuses on Medicare provisions aimed at improving quality and decreasing costs. The Medicare provisions include value-based payment programs, increased funding of comparative effectiveness research, reduced hospital payments for avoidable readmissions and healthcare acquired conditions and infections. New programs to evaluate alternative payment methodologies that promote care coordination such as Accountable Care Organizations and bundled physician and hospital payments have been established and will continue to be implemented during the next several years that could impact the value and payment for our products. See Item 1A. Risk Factors for a further discussion.






Becton Dickinson's Comment on Sales, Marketing and Customers


BD’s products are marketed in the United States and internationally through independent distribution channels and directly to end-users by BD and independent sales representatives. Order backlog is not material to BD’s business inasmuch as orders for BD products generally are received and filled on a current basis, except for items temporarily out of stock. BD’s worldwide sales are not generally seasonal, with the exception of certain medical devices in the BD Medical segment, and respiratory and flu diagnostic products in the BD Diagnostics segment, which relate to seasonal diseases such as influenza.

Most of our customers and healthcare providers typically rely on third-party payers, including government programs and private health insurance plans, to reimburse some or all of the cost of the procedures, products and services they provide. Our devices are subject to worldwide regulations regarding reimbursement developed by government agencies, including the Centers for Medicare and Medicaid Services (CMS) in the United States; the National Health Service in the United Kingdom; the Joint Federal Committee in Germany; the Commission d’Evaluation des Produits et prestations in France; the Ministry for Health, Labor and Welfare in Japan; the Ministry of Health and the National Development and Reform Commission in China; among many others. In addition, our devices are also subject to reimbursement policies issued by private insurance companies and managed care organizations. The manner and level of reimbursement in any given case may depend on the site of care, the procedure(s) performed, the final patient diagnosis, the device(s) and/or drug(s) utilized, the available budget, or a combination of these factors, and coverage and payment levels are determined at each payer’s discretion. The coverage policies and reimbursement levels of these third-party payers may impact the decisions of healthcare providers and facilities regarding which medical products they purchase and the prices they are willing to pay for those products. Thus, changes in reimbursement levels or methods may either positively or negatively impact sales of BD products.

While BD is actively engaged in promoting the value propositions of its products for payer, provider, and patient stakeholders, and it employs various efforts and resources to positively impact coverage, coding and payment processes in this regard, it has no direct control over payer decision-making with respect to coverage and payment levels for BD products. Many third-party payers are seeking to control the growth of healthcare expenditures and have developed specific payment and delivery mechanisms to support these cost control efforts. These mechanisms include payment reductions, pay for performance measures, quality-based performance payments, restrictive coverage policies, bidding and tender mechanics, studies to compare the effectiveness of therapies and use of technology assessments. These changes have created an increased emphasis on the delivery of more cost-effective and quality-driven healthcare. As government programs, including CMS and many other national healthcare programs, seek to expand healthcare coverage for their citizens, they have at the same time sought to control costs by limiting the amount of reimbursement they will pay for particular procedures, products or services.

As BD’s product offerings are diverse across many healthcare settings, they are affected to varying degrees by the many payment systems. Therefore, individual countries, product lines or product classes may be impacted by changes to these systems. Notably the Patient Protection and Affordable Care Act (“PPACA”) provides for numerous, substantive changes to U.S. healthcare payment systems. The law focuses on Medicare provisions aimed at improving quality and decreasing costs. The Medicare provisions include value-based payment programs, increased funding of comparative effectiveness research, reduced hospital payments for avoidable readmissions and healthcare acquired conditions and infections. New programs to evaluate alternative payment methodologies that promote care coordination such as Accountable Care Organizations and bundled physician and hospital payments have been established and will continue to be implemented during the next several years that could impact the value and payment for our products. See Item 1A. Risk Factors for a further discussion.










BDX's vs. Customers, Data

(Revenue and Income for Trailing 12 Months, in Millions of $, except Employees)



COMPANY NAME MARKET CAP REVENUES INCOME EMPLOYEES
Becton Dickinson And Company 67,078.56 19,716.00 1,332.00 77,000
Quest Diagnostics Inc 16,503.20 9,287.00 899.00 49,000
Neogenomics Inc 1,866.44 609.85 -84.23 2,000
Cvs Health Corporation 73,904.11 360,935.00 7,350.00 300,000
Davita Inc 12,672.96 12,338.00 1,092.29 69,000
Fresenius Medical Care Ag 5,750.90 21,788.05 820.35 1,254
Heartland Media Acquisition Corp 202.86 0.00 4.01 0
The Kroger Co 39,883.22 148,362.00 2,243.00 420,000
Laboratory Corporation Of America Holdings 18,167.11 11,560.30 434.20 75,500
Rite Aid Corp 35.86 23,475.49 -1,635.20 50,000
Tenet Healthcare Corp 13,570.67 20,895.00 3,349.00 108,000
Walgreens Boots Alliance Inc 9,760.94 136,108.00 -3,821.00 325,000
Abbvie Inc 307,810.53 54,403.00 6,004.00 50,000
Amgen Inc 180,079.92 29,532.00 3,763.00 24,200
Senestech Inc 2.76 1.38 -7.51 27
SUBTOTAL 680,211.48 829,295.07 20,410.91 1,473,981


Help

About us

Advertise

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research. 
   Copyright © 2024 CSIMarket, Inc. All rights reserved. This site uses cookies to make your browsing experince better. By using this site, you agree to the Terms of Service and Privacy Policy - UPDATED (Read about our Privacy Policy)

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com